Last reviewed · How we verify

NCT04139629

Cohort Study Investigating the Association Between Antichlamydial Antibody Positivity and ART Outcomes in Women With TFI

Status unknown NA Last updated 24 August 2021
What this trial tests

NA trial testing antichlamydial antibody test in Antichlamydial Antibodies in 292 participants. Status unknown.

Timeline
25 October 2019
Primary endpoint
30 January 2020
30 October 2021

Quick facts

Lead sponsorD.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposediagnostic
Enrollment292
Start date25 October 2019
Primary completion30 January 2020
Estimated completion30 October 2021
Sites1 location across Russia

Drugs / interventions tested

Conditions studied

Sponsor

D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology

Who can join

Adults 20 to 41, female only, with Antichlamydial Antibodies or Chlamydia Trachomatis Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In a prospective cohort study investigators will examine characteristics and clinical outcomes of treatment with ART in women with tubal factor infertility (TFI) with regard to seropositivity to antichlamydial antibodies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04139629.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing